ERBB2 and breast carcinoma: Since breast cancer is a complex disease with high heterogeneity, molecular subtypes including Luminal A, Luminal B, HER2 positive and triple negative breast cancer(TNBC) identified by gene expression profile or immunohistochemical panel are widely used in clinical practice, and each subtype has discrete prognostic pattern and treatment response, plenty of TILs related studies showed conflicting results in breast cancer field, the prognostic value of TILs and/or TILs subsets was not yet determined.